SINGAPORE INSTITUTE OF ADVANCED MEDICINE HOLDINGS LTD.
(Incorporated in the Republic of Singapore on 24 November 2011)
(Company Registration Number: 201134046D)

RESULTS OF ANNUAL GENERAL MEETING

Pursuant to Rule 704(15) of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited (the "**Catalist Rules**"), the Board of Directors ("**Board**") of Singapore Institute of Advanced Medicine Holdings Ltd. (the "**Company**", and together with its subsidiaries, the "**Group**") wishes to announce that, at the annual general meeting of the Company held on 30 October 2026 (the "**AGM**"), all resolutions relating to the matters set out in the notice of AGM dated 15 October 2026 were duly passed by the shareholders of the Company at the AGM by way of poll.

The information as required under Rule 704(15) of the Catalist Rules is as set out below:

(a) **Breakdown of all valid votes cast at the AGM:**

Resolution number and details	Total number of shares represented by votes for and against the relevant resolution	For		Against	
		Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
Resolution 1: To receive and adopt the Directors' Statement and Audited Financial Statements of the Company and the Group for the financial year ended 30 June 2026, together with the Independent Auditors' Report thereon.	1,182,729,160	1,182,729,160	100	0	0
Resolution 2: To approve the payment of Directors' fees of S$200,000 for the financial year ending 30 June 2027, to be paid half-yearly in arrears.	1,182,729,160	1,182,729,160	100	0	0
Resolution 3: To re-elect Mr Yeo Seng Lye Paul as a Director of the Company.	1,181,424,815	1,181,424,815	100	0	0

Resolution number and details	Total number of shares represented by votes for and against the relevant resolution	For		Against	
		Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
Resolution 4: To re-elect Dato' Sri Lee Kok Chuan as a Director of the Company.	1,182,729,160	1,182,729,160	100	0	0
Resolution 5: To re-elect Mr Levin Tan Eng Kien as a Director of the Company.	1,182,729,160	1,182,729,160	100	0	0
Resolution 6: To re-elect Mdm Rose Tan Hoon Hoon as a Director of the Company.	1,182,729,160	1,182,729,160	100	0	0
Resolution 7: To re-appoint Messrs Foo Kon Tan LLP as Auditor of the Company and to authorise the Directors to fix their remuneration.	1,182,729,160	1,182,729,160	100	0	0
Resolution 8: To authorise the Directors to allot and issue shares and convertible securities.	1,182,729,160	1,182,729,160	100	0	0
Resolution 9: To authorise the Directors to allot and issue shares under Singapore Institute of Advanced Medicine Holdings Performance Share Plan.	1,182,729,160	1,182,729,160	100	0	0

(b) **Re-election of Directors – Ordinary Resolutions 3, 4, 5 and 6**

Mr Yeo Seng Lye Paul, Dato' Sri Lee Kok Chuan, Mr Levin Tan Eng Kien and Mdm Rose Tan Hoon Hoon were re-elected as Directors of the Company at the AGM.

(i) Mr Yeo Seng Lye Paul will continue to serve as the Executive Director and Chief Operating Officer of the Company.

(ii) Dato' Sri Lee Kok Chuan, a Non-Executive and Non-Independent Director of the Company, will continue to serve as a Member of the Audit Committee of the Company. He is considered non-independent by the Board for the purposes of Rule 704(7) of the Catalist Rules.

(iii) Mr Levin Tan Eng Kien, a Non-Executive and Non-Independent Director of the Company, will continue to serve as a Member of both the Nominating Committee and the Remuneration Committee of the Company.

(iv) Mdm Rose Tan Hoon Hoon, an Independent Director of the Company, will continue to serve as the Chairman of the Nominating Committee and a Member of the Audit Committee of the Company. She is considered independent by the Board for the purposes of Rule 704(7) of the Catalist Rules.

(c) **Details of parties who are required to abstain from voting on any resolution(s)**

In accordance with the rules of the Singapore Institute of Advanced Medicine Holdings Performance Share Plan ("**SIAMH PSP**"), all Directors and employees of the Company and its subsidiaries, who are also shareholders and who hold unvested awards under the SIAMH PSP, are required to abstain from voting on Resolution 9 relating to the SIAMH PSP.

As there were no shareholders holding unvested awards under the SIAMH PSP at the date of the AGM, no shareholders were required to abstain from voting on Resolution 9.

(d) **Name of firm appointed as scrutineer**

CNP Business Advisory Pte. Ltd. was appointed as scrutineer for the AGM.

BY ORDER OF THE BOARD

Dr Djeng Shih Kien
Executive Director and Chief Executive Officer
30 October 2026

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.